Masashi Sakayori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masashi Sakayori has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Keiichiro Yoshioka
Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan
2 shared publications- Mitsuhiro Abe
Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
2 shared publications - Akimasa Sekine
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-Ku, Yokohama, 236-0051, Japan
1 shared publication - Eri Hagiwara
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
1 shared publication - Erina Tabata
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-Ku, Yokohama, 236-0051, Japan
1 shared publication - Hajime Kasai
Department of Medical Education, Graduate School of Medicine, Chiba University, Chiba, Japan
1 shared publication
Latest Publications
- 13 September 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (1) , 105-108
Incidence of acute exacerbation in patients with interstitial lung disease after COVID-19 vaccination
- 13 September 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (1) , 105-108
Incidence of acute exacerbation in patients with interstitial lung disease after COVID-19 vaccination
- Open Access
- 27 September 2021
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 34, 101521
Exacerbation of autoimmune pulmonary alveolar proteinosis that improved with lone treatment of complicating nontuberculous mycobacterial infection: A case report
- 27 September 2021
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 34, 101521
Open AccessExacerbation of autoimmune pulmonary alveolar proteinosis that improved with lone treatment of complicating nontuberculous mycobacterial infection: A case report
- Open Access
- 1 July 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 2295-2303
Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
Although pirfenidone (PFD) is a key drug for the treatment of idiopathic pulmonary fibrosis (IPF), differences in tolerability between elderly and young patients remain unclear. This study aimed to investigate age-related differences in adverse drug reactions to PFD and to evaluate whether patient age influences the safety and tolerability of PFD in clinical practice. One hundred fifty-four patients with IPF were treated with PFD in our institution between May 2009 and April 2017; these patients were classified into 2 groups on the basis of age: ≥75 years of age (elderly patients) and <75 years of age (younger patients). In each group, the clinical course, laboratory data, radiographic findings, adverse events, and tolerability of PFD at 6 months and 1 year after administration were retrospectively analyzed. Among the 120 patients examined in this study, 31 patients (26%) were ≥75 years of age. The continuation rate of PFD at 1 year in the elderly patient group was significantly lower (n=11 [35%] vs 57 [64%], p=0.007) than in the younger patient group. Regarding adverse drug reactions to PFD, the incidence of gastrointestinal disorders including anorexia (n=24 [77%] vs 40 [45%], p=0.002) and the discontinuation caused by gastrointestinal disorders (n=11 [35%] vs 13 [15%], p=0.019) were significantly higher in elderly patients than those in younger patients. However, with the exception of gastrointestinal disorders, other adverse drug reactions did not significantly differ between elderly and younger patients. Compared with younger patients, elderly patients with IPF had a higher incidence of gastrointestinal disorders, along with an increased discontinuation rate of PFD. More careful management of gastrointestinal disorders may be required to ensure continuation of PFD in elderly patients.
- 1 July 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 2295-2303
Open AccessDifferences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
Although pirfenidone (PFD) is a key drug for the treatment of idiopathic pulmonary fibrosis (IPF), differences in tolerability between elderly and young patients remain unclear. This study aimed to investigate age-related differences in adverse drug reactions to PFD and to evaluate whether patient age influences the safety and tolerability of PFD in clinical practice. One hundred fifty-four patients with IPF were treated with PFD in our institution between May 2009 and April 2017; these patients were classified into 2 groups on the basis of age: ≥75 years of age (elderly patients) and <75 years of age (younger patients). In each group, the clinical course, laboratory data, radiographic findings, adverse events, and tolerability of PFD at 6 months and 1 year after administration were retrospectively analyzed. Among the 120 patients examined in this study, 31 patients (26%) were ≥75 years of age. The continuation rate of PFD at 1 year in the elderly patient group was significantly lower (n=11 [35%] vs 57 [64%], p=0.007) than in the younger patient group. Regarding adverse drug reactions to PFD, the incidence of gastrointestinal disorders including anorexia (n=24 [77%] vs 40 [45%], p=0.002) and the discontinuation caused by gastrointestinal disorders (n=11 [35%] vs 13 [15%], p=0.019) were significantly higher in elderly patients than those in younger patients. However, with the exception of gastrointestinal disorders, other adverse drug reactions did not significantly differ between elderly and younger patients. Compared with younger patients, elderly patients with IPF had a higher incidence of gastrointestinal disorders, along with an increased discontinuation rate of PFD. More careful management of gastrointestinal disorders may be required to ensure continuation of PFD in elderly patients.